ATE489624T1 - Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose - Google Patents
Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognoseInfo
- Publication number
- ATE489624T1 ATE489624T1 AT06752069T AT06752069T ATE489624T1 AT E489624 T1 ATE489624 T1 AT E489624T1 AT 06752069 T AT06752069 T AT 06752069T AT 06752069 T AT06752069 T AT 06752069T AT E489624 T1 ATE489624 T1 AT E489624T1
- Authority
- AT
- Austria
- Prior art keywords
- prognosis
- antibodies against
- cancer diagnosis
- clinical cancer
- histone modifications
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 108010033040 Histones Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000012986 modification Methods 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 230000002055 immunohistochemical effect Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67602105P | 2005-04-29 | 2005-04-29 | |
| US77823506P | 2006-03-01 | 2006-03-01 | |
| PCT/US2006/016765 WO2006119264A2 (en) | 2005-04-29 | 2006-05-01 | Antibodies against histone modifications for clinical diagnosis and prognosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE489624T1 true ATE489624T1 (de) | 2010-12-15 |
Family
ID=37308614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06752069T ATE489624T1 (de) | 2005-04-29 | 2006-05-01 | Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080248039A1 (de) |
| EP (2) | EP1896849B1 (de) |
| AT (1) | ATE489624T1 (de) |
| CA (1) | CA2607327A1 (de) |
| DE (1) | DE602006018458D1 (de) |
| WO (1) | WO2006119264A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319376D0 (en) * | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
| WO2008130516A1 (en) * | 2007-04-11 | 2008-10-30 | Manel Esteller | Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer |
| EP2419737A4 (de) * | 2009-04-14 | 2013-02-13 | Univ California | Histonmodifizierungsmuster für die klinische diagnose und prognose von krebs |
| GB201303576D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for predicting therapy efficacy using nucleosome structure biomarkers |
| CN113075408B (zh) * | 2021-03-16 | 2024-08-23 | 上海市同仁医院 | 一种利用组蛋白作为内参的免疫组织化学定量方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2460679A1 (en) * | 2001-05-11 | 2003-11-20 | Michael Mcarthur | Dna microarrays comprising active chromatin elements and comprehensive profiling therewith |
| CA2456010A1 (en) * | 2001-08-03 | 2003-02-20 | University Of Virginia Patent Foundation | Phosphorylated histone h2b as an apoptosis marker |
| CA2476835A1 (en) * | 2002-02-20 | 2003-08-28 | University Of Virginia Patent Foundation | A non-invasive diagnostic test utilizing histone modification markers |
| EP1403639A1 (de) * | 2002-09-30 | 2004-03-31 | G2M Cancer Drugs AG | Antikörper als Diagnosemittel in der medizinischen Therapie mit Histondeacetylase-Hemmern |
| GB0319376D0 (en) * | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
| CA2591717A1 (en) * | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
-
2006
- 2006-05-01 EP EP06752069A patent/EP1896849B1/de not_active Not-in-force
- 2006-05-01 DE DE602006018458T patent/DE602006018458D1/de active Active
- 2006-05-01 CA CA002607327A patent/CA2607327A1/en not_active Abandoned
- 2006-05-01 AT AT06752069T patent/ATE489624T1/de not_active IP Right Cessation
- 2006-05-01 WO PCT/US2006/016765 patent/WO2006119264A2/en active Application Filing
- 2006-05-01 EP EP10009991.0A patent/EP2267450B1/de not_active Not-in-force
- 2006-05-01 US US11/912,429 patent/US20080248039A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2267450A3 (de) | 2011-04-13 |
| EP2267450B1 (de) | 2015-01-28 |
| EP1896849A4 (de) | 2009-01-14 |
| DE602006018458D1 (de) | 2011-01-05 |
| EP2267450A2 (de) | 2010-12-29 |
| EP1896849B1 (de) | 2010-11-24 |
| WO2006119264A3 (en) | 2006-12-21 |
| EP1896849A2 (de) | 2008-03-12 |
| US20080248039A1 (en) | 2008-10-09 |
| WO2006119264A2 (en) | 2006-11-09 |
| CA2607327A1 (en) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2484142T3 (es) | Diagnóstico molecular y clasificación del melanoma maligno | |
| BRPI0607450A2 (pt) | anticorpos que se ligam a epha2 e métodos para sua utilização | |
| ATE534905T1 (de) | Cop1-moleküle und verwendungen davon | |
| EA201370063A1 (ru) | Фосфолипидом рака | |
| ATE535805T1 (de) | Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen | |
| BRPI0720371B8 (pt) | métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata | |
| DK1889059T3 (da) | Fremgangsmåde til forbedret immunoassay | |
| BRPI0606685A2 (pt) | anticorpos gitr para o diagnóstico de nsclc | |
| IL180997A0 (en) | Diagnostic methods and kits utilizing platelet biomarkers for cancer | |
| DE60335022D1 (de) | Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel | |
| EP1842065A4 (de) | Diagnose- und prognoseverfahren von epithelkrebs | |
| ATE483972T1 (de) | Reagenzien und verfahren für krebsprognose und pathologische einstufung | |
| WO2008148072A3 (en) | Disease-associated genetic variations and methods for obtaining and using same | |
| EP1930426A4 (de) | Zusammensetzung und verfahren zur diagnose von nierenkrebs und abschätzung der prognose eines nierenkrebspatienten | |
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| ATE489624T1 (de) | Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose | |
| DE602007007958D1 (de) | Antikörper gegen ein epitop auf agr2, assays und hybridome | |
| Leung et al. | Ovarian cancer biomarkers: current state and future implications from high-throughput technologies | |
| WO2007089734A3 (en) | Proteomic fingerprinting of human ivf-derived embryos: identification of biomarkers of developmental potential | |
| WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
| WO2008131261A3 (en) | Peptide biomarkers of cardiovascular disease | |
| ATE406579T1 (de) | Verfahren zur diagnose von tumoren | |
| DE602004011481D1 (de) | Kombinierung von mehreren unabhängigen Informationenquellen für die Klassifizierung von Prüflingen | |
| MXPA06012232A (es) | Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas. | |
| CY1113290T1 (el) | Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |